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Abstract 
Perfluorinated alkylate substances (PFASs) are highly persistent and may cause immunotoxic 
effects. PFAS-associated attenuated antibody responses to childhood vaccines may be affected 
by PFAS exposures during infancy, where breastfeeding adds to PFAS exposures. Of 490 
members of a Faroese birth cohort, 275 and 349 participated in clinical examinations and 
provided blood samples at ages 18 months and 5 years. PFAS concentrations were measured at 
birth and at the clinical examinations. Using information on duration of breastfeeding, serum-
PFAS concentration profiles during infancy were estimated. As outcomes, serum concentrations 
of antibodies against tetanus and diphtheria vaccines were determined at age 5. Data from a 
previous cohort born eight years earlier were available for pooled analyses. Prenatal exposure 
showed inverse associations with the antibody concentrations five years later, with decreases by 
up to about 20% for each two-fold higher exposure, while associations for serum concentrations 
at ages 18 months and 5 years were weaker. Modeling of serum-PFAS concentration showed 
levels for age 18 months that were similar to those measured. Concentrations estimated for ages 
3 and 6 months showed the strongest inverse associations with antibody concentrations at age 5 
years, particularly for tetanus. Joint analyses showed statistically significant decreases in tetanus 
antibody concentrations by 19% to 29% at age 5 for each doubling of the PFAS exposure in 
early infancy. These findings support the notion that the developing adaptive immune system is 
particularly vulnerable to immunotoxicity during infancy. This vulnerability appears to be the 
greatest during the first 6 months after birth, where PFAS exposures are affected by breast-
feeding. 
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Introduction 
Industrial chemicals are not routinely tested for immunotoxicity, but recent evidence 
suggests that some environmental chemicals may harm immune functions, perhaps in particular 
during early development of the adaptive immune system (Dietert and Dewitt 2010; Dietert 
2014). Among recently confirmed immunotoxicants, the perfluorinated alkylate substances 
(PFASs) have been widely applied for a multitude of purposes, and due to their persistence, 
human PFAS exposures now occur globally (Lindstrom et al. 2011). Women eliminate PFASs 
via lactation (Mondal et al. 2014), and a child’s exposure in infancy is strongly affected by 
transfer via human milk (Liu et al. 2011; Mogensen et al. 2015b). With human milk being a main 
source of exposure early postnatally, serum-PFAS concentrations in infancy could potentially be 
estimated from the exposure level at birth and the duration of breastfeeding. 
Experimental evidence so far supports the possibility that early development of the 
adaptive immune system may be particularly vulnerable to PFAS exposure (Dietert 2014), but 
the U.S. National Toxicology Program recently concluded that specific immune cell 
vulnerabilities and their dependence upon developmental stages are unclear so far (National 
Toxicology Program 2016). Unfortunately, epidemiology studies of toxicant exposures in 
infancy are problematic due to the difficulty in obtaining blood samples from small children. 
In addition, immune function tests are not easily applied in epidemiological studies of 
small children. However, serum-antibody concentrations induced by routine immunizations have 
been recommended for this purpose (van Loveren et al. 1999) due to the advantage that a 
vaccination constitutes a well-defined stimulation of the adaptive immune system (Ljungman 
2013). The first vaccinations in infancy stimulate the virgin immune system, and subsequent re-
vaccinations trigger the primary repertoire and response as well as secondary responses (Capua 
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et al. 2013). The immune response against specific protein antigens (such as tetanus and 
diphtheria toxoids) thereby reflects a variety of functions, such as antigen presentation, antigen 
processing, T-cell help, B-cell activation, germinal center B-cell reactivation and B-cell 
maturation (Schatz et al. 1998). 
Recent studies relied on serum concentrations of antibodies specifically directed against 
vaccines that were administered in infancy (Grandjean et al. 2012; Granum et al. 2013), but none 
of them attempted to link the PFAS-associated decreases in antibody concentrations to past 
exposures during infancy. Because a sizable proportion of fully-vaccinated children may have 
vaccine responses that provide incomplete protection against the disease (Grandjean et al. 2012), 
PFAS immunotoxicity may be of substantial public health relevance in regard to the specific 
vaccine responses and possibly also in regard to other immune functions. 
The present study extends earlier reports on inverse associations between serum 
concentrations of PFASs and vaccine-specific antibodies in children (Grandjean et al. 2012; 
Mogensen et al. 2015a), now in a new prospective birth cohort in the Faroe Islands (Cohort 5, 
born in 2007-2009). Serum samples from ages 18 months and five years were analyzed for 
PFASs, and serum-PFAS concentrations during infancy were modeled. To increase the statistical 
power of the study, joint statistical analyses were conducted with a previous birth cohort 
(Grandjean et al. 2012), where PFAS exposures were higher. 
Methods 
Study population 
The Faroese Cohort 5 of 490 children was recruited from births at the National Hospital 
in Tórshavn, Faroe Islands, during 2007-2009 (Kim et al. 2014; Timmermann et al. 2017). A 
maternal serum sample was collected about two weeks after the expected term date. As part of 
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the government-supported health care system, Faroese children receive vaccinations against 
diphtheria and tetanus at ages 3 months, 5 months, and 12 months, and a booster at age 5 years. 
This way, the same amount of vaccine and associated alum adjuvant were applied at the same 
ages. In this population, PFAS exposures are associated with marine food contamination (Weihe 
et al. 2008), and these substances do not occur as contaminants of local drinking water (Eriksson 
et al. 2013). 
All cohort members were invited for clinical follow-up at ages 18 months and 5 years 
(before the age-5 booster), where maternal interview, physical examination of the child, and 
blood sampling took place. Detailed vaccination records were available, as were obstetrics 
information, and questionnaire information on duration of breastfeeding, past medical history 
and current health status. In order to increase the statistical power, this study included data from 
the earlier Cohort 3 (born 1997-2000), which had formed the basis of previous reports 
(Grandjean et al. 2012; Grandjean and Budtz-Jorgensen 2013; Mogensen et al. 2015a). Apart 
from being about eight years apart and therefore differing in exposure levels and profiles 
(median concentrations of PFHxS, PFOS, PFOA, and perfluorodecanoate (PFDA) were lower in 
Cohort 5, while the concentrations of perfluorononanoate (PFNA) were slightly higher compared 
to Cohort 3), the two cohorts are highly similar, and methods were virtually identical (Cohort 3 
sampled maternal blood in late pregnancy) (Dalgard et al. 2016; Timmermann et al. 2017). 
The study protocol was approved by the Faroese ethical review committee and by the 
institutional review board at Harvard T.H. Chan School of Public Health. Written informed 
consent was obtained from all mothers. 
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Immunotoxicant exposures  
The PFAS concentrations were measured in all serum samples by online solid-phase 
extraction followed by high-pressure liquid chromatography with tandem mass spectrometry 
(Haug et al. 2009; Grandjean et al. 2012). The analyses quantified the five major PFAS, i.e., 
perfluorohexanesulfonic acid (PFHxS), PFOA, PFOS, PFNA, and PFDA. Within-batch and 
between-batch imprecision levels (coefficients of variation) for all five PFASs were < 3% and 5-
6%, respectively, in agreement with excellent results obtained in regular comparisons organized 
by the German Society of Occupational Medicine. 
As developmental exposure to polychlorinated biphenyls (PCBs) can also reduce 
vaccine responses (Heilmann et al. 2010), this study also measured maternal serum-PCB concen-
trations and used the sum of the three major congeners as an indicator of the total PCB exposure 
(Grandjean et al. 2012). 
Vaccine antibodies  
Focus was maintained on tetanus and diphtheria, as these toxoid vaccines trigger immune 
system responses involving both T- and B-cells (Schatz et al. 1998). Serum concentrations of 
IgG antibodies were again measured by the Danish vaccine producer (Statens Serum Institut 
[SSI], Copenhagen, Denmark) using an enzyme-linked immunosorbent assay for tetanus 
(Hendriksen et al. 1988), while diphtheria antibodies were measured using a standard Vero cell-
based neutralization assay employing two-fold dilutions (Miyamura et al. 1974). For both assays, 
calibration was performed using international and local standard antitoxins. We used the cut-off 
limit of 0.1 IU/mL for both vaccine antibodies, as recommended by the SSI, to determine 
whether antibody concentrations could be considered protective. 
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Statistical methods 
Due to skewed distributions, antibody concentrations and serum-PFAS concentrations 
were log-transformed (base 2) before entering the models. We first applied standard multiple 
regression analyses, where log-transformed PFAS concentrations at different ages were included 
as independent variables one at a time. More advanced models relied on structural equations 
(Mogensen et al. 2015a). All analyses were adjusted for age and sex. Joint models were 
developed for the combined data that also included the data from Cohort 3 (Grandjean et al. 
2012), where cohort identity was included as an additional covariate that was allowed to interact 
with sex, age and PFAS concentrations. Effects were expressed as the relative change in the 
antibody concentration associated with a doubling in the PFAS concentration. In sensitivity 
analyses, it was tested whether cesarean section (N = 63) played a role, and likewise possible 
effects of prenatal PCB exposure and duration of breastfeeding were considered. 
Because previous results on Cohort 3 showed that PFAS concentrations in childhood 
depended on the duration of breastfeeding (in months) (Mogensen et al. 2015b), early postnatal 
serum-PFAS concentrations were modeled from their dependence on the duration of 
breastfeeding in a piece-wise linear model: 
log PFASi,a = µ + α exclusivei,a + β partiali,a + γ nomilki,a + Ui + εi,a,                (1) 
where log PFASi,a is the log-transformed serum concentration of child i at age a, while 
exclusivei,a, partiali,a, and nomilki,a indicate the number of months that the child was exclusively 
breastfed, partially breastfed, and not breastfed at all by age a. The variable Ui accounts for 
within-child correlation, i.e., the fact that a child above the mean at one time-point will also tend 
to be higher at other time points. The last term εi,a is a random measurement error. So, at birth, 
the log transformed serum concentration is given by the intercept (µ + Ui), which is allowed to 
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be specific for each child. During the period of exclusive breastfeeding, the log-transformed 
concentration is assumed to change by a slope of α. Likewise, during partial breastfeeding the 
slope is β, and after weaning, the slope is γ. This model was fitted to the data from the two 
cohorts separately, and a joint model was then fitted under the assumption that breastfeeding 
effects were homogeneous while allowing the serum-PFAS concentration (µ) to depend on 
cohort. This part of the model allows, in principle, a prediction of the serum-PFAS concentration 
at any given age, based on the breastfeeding history up to that age. Estimated concentrations for 
age 18 months were then compared with measured serum concentrations at that age. 
A second part of the structural equation model links the exposure to the vaccine 
antibody concentration at age 5 using a linear regression similar to the standard models used for 
observed exposures, i.e., 
log antibodyi = θ0 + θ1 log PFASi,a + θ2sexi + θ3age60i + εi                                   (2)  
where age60i is the child’s age (months) at the 5-year examination. In this model, we estimated 
the effect of a doubling of the exposure at ages 3, 6, and 12 months.  As in the regression 
analyses, the calculations allowed for differences between cohorts by allowing the intercept and 
the effects of the covariates (age and sex) to depend on cohort. We focused on the two major 
PFASs that showed the strongest associations for prenatal exposures. 
The calculations were carried out for the two cohorts separately and jointly. As maternal 
serum in Cohort 5 was not obtained at childbirth, sensitivity analyses were carried out to assess 
whether the number of days between parturition and blood sampling for PFAS analysis affected 
the estimated relation between breastfeeding and the child’s PFAS-concentrations. This was 
done by changing model (1) for the concentration at birth (a = 0) so that it also depended on the 
interval (days) between childbirth and blood sampling, as well as a covariate indicating whether 
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the child was breastfed, and an interaction term. This way, allowance was made for the 
possibility that maternal serum-PFAS concentrations measured post parturition may have been 
affected by changes in distribution volume or transfer of PFASs from mother to child via 
lactation. The algorithm also allowed for a possible beneficial effect of breastfeeding on the 
child’s antibody concentration, as an additional covariate in model (2) indicated whether the 
child had been breastfed for at least 6 months. 
Regression analyses were conducted using SAS version 9.4 (SAS Institute, Inc. Cary, 
NC), while structural equation models were fitted using the R software, the lava package. 
Results 
A total of 381 children (77% of 495 cohort members) participated in the age-5 
examinations, and 370 (97%) of these had also participated at age 18 months. The characteristics 
of the 349 children who provided sufficient serum for analyses at age 5 and the 275 children who 
additionally provided sufficient serum for analyses at age 18 months are shown in Table 1. 
PFOS was by far the most prevalent PFAS in Cohort 5 with a median age-5 serum 
concentration of 4.7 ng/ml. PFOS and PFOA concentrations decreased from age 18 months to 
age 5 years (Table 1). Moderate correlations were observed between the concentrations at ages 
18 months and 5 years of the same PFAS (r up to 0.7 after log transformation), though somewhat 
stronger between the different PFASs at each age (r up to 0.9 at age 18 months and up to 0.8 at 
age 5 years). The close correlations prevented meaningful adjustment for concomitant PFAS 
exposures. In regard to the antibody concentrations, they showed clear decreases from age 18 
months to the (pre-booster) examination at age 5 years (Table 1). At age 5, 152 (44%) children 
had antibody concentrations lower than the protective level of 0.1 IU/mL for diphtheria and 126 
(36%) for tetanus. 
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Multiple regression analyses showed inverse associations between serum-PFAS 
concentrations and antibody concentrations in most analyses (Table 2). In Cohort 5, the strongest 
inverse associations were found for tetanus, especially in regard to prenatal PFAS exposures. For 
all three sets of serum analyses, PFOA showed the strongest associations with lower tetanus 
antibody concentrations at age 5. Little difference occurred between the cohorts, and joint 
analyses again revealed clear inverse associations for PFOA. In regard to prenatal exposures, 
both PFOS and PFOA showed clear inverse associations with antibody levels, and inclusion of 
the interval between childbirth and maternal blood sampling in Cohort 5 did not affect the 
results. Cross-sectional comparisons in the joint analysis at age 5 showed inverse associations 
also for PFNA and PFDA, though in regard to diphtheria only. The PCB concentration in 
maternal pregnancy serum correlated poorly with the child’s serum-PFAS concentrations (r 
between 0.0 and 0.3), similar to previous results (Grandjean et al. 2012), and adjustment for 
developmental PCB exposure had no appreciable effect on the associations for the PFASs. 
Likewise, adjustment for cesarean section did not substantially affect the results. 
Duration of breastfeeding is closely associated with the child’s postnatal PFAS-
concentrations (Table 3), even for PFHxS, but differences between cohorts 3 and 5 were minor. 
Serum-PFAS concentrations during infancy were then estimated on the basis of breastfeeding 
duration. Estimated serum-PFAS concentrations extended to age 18 months correlated closely 
with the measured serum concentrations in Cohort 5 at this age (Figure 1), thereby supporting the 
validity of the calculations. The predicted concentrations of PFOS and PFOA in early infancy 
tended to be inversely associated with the antibody concentrations at age 5 (Table 4), most 
clearly for PFOA in regard to tetanus, where a doubled exposure led to a decrease in the antibody 
concentration of about 30% at age 5 years. Tendencies were similar in the two cohorts, whether 
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cohort-specific or based on the joint model that assumed identical relationships between 
breastfeeding and PFAS exposure in the two cohorts. The results presented in Table 4 are 
adjusted for duration of breastfeeding, but the direct effects of breastfeeding on antibody 
concentrations tended to be weakly negative, and the impact on the regression coefficients for 
the PFASs was minor. 
Discussion 
The present prospective study aimed at exploring the role of PFAS exposure in infancy in 
regard to responses to routine childhood immunizations in terms of antibody concentrations 
measured at age 5 years, i.e., four years after the most recent (third) vaccination. While greater 
vulnerability to immunotoxicants is suspected during early maturation of the adaptive immune 
system, previous studies have not been able to elucidate this possibility, as blood samples are 
difficult to collect from healthy infants. While serum-PFAS concentrations tend to be quite stable 
in adults (Zhang et al. 2013), the concentrations in children are much more variable, possibly 
because of age-dependent changes in exposure sources (Kato et al. 2009; Lindstrom et al. 2011). 
Accordingly, our results showed only modest correlations between serum-PFAS concentrations 
at birth and at ages 18 months and 5 years, likely due to differences in the transfer via breast-
feeding (Mogensen et al. 2015b). For several industrial chemicals, breast milk is known to serve 
as an exposure pathway (Grandjean and Jensen 2004; Stefanidou et al. 2009); our observation 
that serum-PFAS concentrations in infants increase substantially with the duration of breast-
feeding is in accordance with this notion. 
In order to estimate PFAS concentrations over time, single-compartment toxicokinetic 
models have been successfully applied, e.g., to calculate past serum-PFOA concentrations after 
cessation of exposure (Seals et al. 2011) and serum-PFAS profiles in children exposed from 
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breastfeeding (Verner et al. 2016). Thus, the present study included both PFAS concentrations 
measured in age 18-month blood samples, and the study also utilized information on the duration 
of exclusive breastfeeding to calculate profiles of serum-PFAS concentrations during infancy. 
Such calculations assume that each child received the same daily amount of milk in 
regard to body weight and that the transfer was constant throughout the duration of exclusive 
breastfeeding without major differences in age-dependent changes in the distribution volume. 
Partial breastfeeding was taken into account, but seemed to be of negligible importance. Despite 
the reservations, the validity of the calculations is supported by the close correlation of observed 
and calculated serum concentrations at age 18 months (Figure 1). Nonetheless, the estimated 
serum-PFAS concentrations in infancy likely involve some random imprecision, thus causing a 
potential bias toward the null (Grandjean and Budtz-Jorgensen 2010) and thereby a possible 
underestimation of the impact of PFAS exposures at infancy on adaptive immune system 
functions. The close correlation seen in Figure 1 suggests that this bias is small. 
As a further consideration, while breastfeeding may transfer toxicants to the infant, it is 
considered advantageous to the developing immune system (Kramer et al. 2007). However, 
although almost all studies on benefits from breastfeeding have ignored any possible bias from 
effects in the opposite direction from immunotoxicants transferred via human milk (Grandjean 
and Jensen 2004; Grandjean et al. 2010), thereby potentially leading to residual negative 
confounding (Choi et al. 2008). As before (Grandjean et al. 2012), we were unable to detect any 
important benefit on the two antibody concentrations associated with the duration of exclusive 
breast-feeding.  
In agreement with our previous studies (Grandjean et al. 2012; Mogensen et al. 2015a), 
the present study confirmed the inverse associations with prenatal exposures for both toxoid 
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antibodies, and our findings now extend these observations by adding information on exposures 
during early childhood. Associations for diphtheria and tetanus differ somewhat, perhaps 
because the diphtheria toxoid is considered a weaker antigen than tetanus and because the 
associations may depend on relative levels of exposure as well as possible differences in age-
dependent vulnerability. Maintenance of the antibody concentrations in serum may be a 
vulnerable target, but previous studies have also documented an inverse association of serum-
PFAS concentrations with the short-term response to vaccinations both in children and in adults 
(Grandjean et al. 2012; Looker et al. 2014; Kielsen et al. 2016). Overall, these findings are in 
accordance with immunotoxic effects demonstrated in laboratory models (National Toxicology 
Program 2016) including in vitro studies of human immune cells (Corsini et al. 2012). Still, the 
detailed mechanisms involved are unclear at present. 
The adaptive immune system is at first dominated by TH2 responses, and TH1 responses 
mature during infancy, thereby allowing proper responses to routine immunizations (Romagnani 
2014). In regard to TH2-related allergy, increased odds of asthma in children were reported at 
elevated PFAS exposures (Dong et al. 2013), although this finding has not been replicated 
(Humblet et al. 2014). Our own studies (i.e., Timmermann et al. 2017) suggested that serum-
PFAS concentrations at age 5 years were associated with increased odds of asthma only among 
the children who had not yet been vaccinated against measles, mumps, and rubella (MMR), 
while the association was reversed among MMR-vaccinated children. Although inhibition of 
antibody responses, perhaps associated with increased risk of allergy development, could 
represent a change in the TH1/TH2 balance (Dong et al. 2011), the relative role of the immune 
system components is complex. The lack of clear evidence on PFAS-associated allergy may in 
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part be due to uncontrolled and variable allergen exposures and the absence of outcome variables 
that are as well-defined and standardized as are vaccine-induced antibodies. 
Our previous results show that an insufficient vaccination response may be remedied at 
least in part by an additional booster (Grandjean et al. 2016). However, while these deficient 
antibody responses do not represent an irreparable insult, the boosters may not remedy any 
additional immune dysfunctions due to PFAS exposures. Among possible consequences of 
insufficient responses to childhood immunizations could be an increased risk of infectious 
diseases other than those that the vaccines aim to protect against. Thus, increased incidence of 
common cold and gastroenteritis in 3-year-olds were recorded in relation to higher maternal 
serum PFOA concentrations during pregnancy (Granum et al. 2013), and a greater incidence of 
infection was also linked with lower vaccine antibody concentrations (Pennings et al 2016). 
Similarly, the incidence of disease with high fever in small children was positively associated 
with the mother’s serum-PFAS concentrations in early pregnancy (Dalsager et al. 2016). While 
serum concentrations of PFOS and PFOA during pregnancy were apparently not associated with 
the total hospitalization rate for infectious diseases in school-age children (Fei et al. 2010), 
quality concerns regarding the serum-PFAS analyses in this cohort (Bach et al. 2015) questions 
the validity of this report. 
The National Toxicology Program recently concluded that both PFOS and PFOA are 
presumed immune hazards for humans (National Toxicology Program 2016), while acknowledg-
ing that the epidemiological studies are unable to attribute PFAS associations to individual 
compounds. PFAS exposures in the Faroes are quite similar to those in the United States (CDC 
2015), but inter-correlations between serum-PFAS concentrations prenatally and at different ages 
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make it difficult to determine accurately the possible age-dependent roles of individual PFASs in 
regard to immune function outcomes. 
Conclusions 
As PFASs are excreted in human milk, serum concentrations in infancy can be estimated 
from serum analyses at birth and the duration of exclusive breastfeeding. Both prenatal 
exposures and estimated serum levels in early infancy showed clear inverse associations with 
antibody concentrations against two toxoid vaccines at age 5 years, while associations with 
PFAS concentrations at ages 18 months and 5 years were weaker. Given that the adaptive 
immune system undergoes crucial maturation during infancy, the results support the high 
vulnerability of the developing immune system. Thus, the present study extends the evidence on 
PFAS-associated deficient antibody responses in children and emphasizes that infants may need 
particular protection as a highly vulnerable sub-population. 
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Figure legend 
Figure 1. Serum concentrations of (A) PFOA and (B) PFOS at age 18 months, as calculated 
from neonatal concentration and the duration of breastfeeding (vertical scale) and compared to 
the measured concentration (horizontal scale). 
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Table 1. Characteristics of children who contributed serum antibody concentrations at the two 
follow-up examinations in Cohort 5. 
 
 
Age 18 months 
(N=275) 
 
Age 5 years 
(N=349) 
  n (%)  n (%) 
Sex, girls  139 (50.6)  173 (49.6) 
 
 
Median (25; 75 
percentile) 
 
Median (25; 75 
percentile) 
Age (months)  18.5 (18.1; 18.9)  60.4 (59.9; 60.9) 
PFOS (ng/ml)  7.1 (4.5; 10.0)  4.7 (3.5; 6.3) 
PFOA (ng/ml)  2.8 (2.0; 4.5)  2.2 (1.8; 2.8) 
PFHxS (ng/ml)  0.2 (0.1; 0.4)  0.3 (0.2; 0.4) 
PFNA (ng/ml)  1.0 (0.6; 1.5)  1.1 (0.8; 1.6) 
PFDA (ng/ml)  0.3 (0.2; 0.4)  0.3 (0.2; 0.5) 
Tetanus (IU/ml)  1.5 (0.5; 3.0)  0.1 (0.1; 0.3) 
Diphteria (IU/ml)  1.6 (0.8; 3.2)  0.1 (0.1; 0.3) 
Duration of exclusive breastfeeding (mo)  5 (4; 6)   
Duration of mixed breastfeeding (mo)  4 (2; 7)   
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Table 2. Change (in percent) of the pre-booster serum-antibody concentrations at age 5 years associated with a doubling of the serum 
concentration of major PFASs at three different times of examination. 
  Cohort 5    Cohort 3    Joint  
 Change 95% Cl p  Change 95% Cl p  Change 95% Cl p 
Tetanus            
At birth            
PFOS  -10.84 -28.34; 10.94 0.30  -10.09 -31.78; 18.51 0.45  -10.55 -24.63; 6.16 0.20 
PFOA  -22.25 -35.25; -6.63 0.007  -10.46 -28.04; 11.41 0.32  -17.59 -28.38; -5.17 0.007 
PFHxS  -11.31 -21.72; 0.49 0.060  -6.30 -15.05; 3.34 0.19  -8.24 -15.05; -0.89 0.029 
PFNA  -7.11 -26.59; 17.53 0.54  11.16 -8.46; 34.98 0.29  3.36 -11.02; 20.07 0.67 
PFDA -8.40 -26.27; 13.79 0.43  -2.45 -18.39; 16.61 0.79  -4.90 -17.14; 9.15 0.47 
18 months            
PFOS  -7.027 -21.63; 10.30 0.40  -8.05 -55.26; 89.01 0.82  -7.08 -21.29; 9.70 0.39 
PFOA  -16.31 -29.04; -1.31 0.034  -19.24 -59.75; 62.05 0.55  -16.47 -28.84; -1.96 0.028 
PFHxS  -2.616 -10.08; 5.47 0.51  -5.18 -51.71; 86.19 0.88  -2.65 -10.05; 5.36 0.50 
PFNA  -6.981 -21.10; 9.67 0.39  -33.79 -64.36; 23.01 0.19  -9.04 -22.43; 6.65 0.24 
PFDA  -5.780 -23.56; 16.13 0.58  -14.47 -56.88; 69.66 0.65  -6.55 -23.47; 14.09 0.50 
60 months            
PFOS  -9.076 -28.10; 14.98 0.43  -11.86 -29.79; 10.65 0.28  -10.52 -24.00; 5.35 0.18 
PFOA  -25.26 -42.63; -2.64 0.031  -13.28 -31.34; 9.54 0.23  -18.75 -31.79; -3.21 0.020 
PFHxS  -4.432 -21.26; 15.99 0.65  -6.29 -17.45; 6.38 0.32  -5.74 -15.22; 4.81 0.27 
PFNA  -10.31 -24.39; 6.40 0.21  -5.87 -21.67; 13.12 0.52  -8.28 -19.06; 3.940 0.18 
PFDA  -1.756 -16.73; 15.91 0.83  -13.55 -26.18; 1.24 0.071  -8.11 -18.03; 3.01 0.15 
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Diphtheria            
At birth            
PFOS  -14.00 -31.59; 8.11 0.20  -38.64 -54.07; -18.04 0.001  -24.47 -36.90; -9.60 0.002 
PFOA  -18.93 -33.16; -1.66 0.033  -16.24 -33.43; 5.40 0.13  -17.82 -29.11; -4.74 0.009 
PFHxS  -3.33 -15.28; 10.30 0.61  -6.41 -15.62; 3.80 0.21  -5.25 -12.66; 2.79 0.19 
PFNA  4.79 -18.21; 34.27 0.71  -14.82 -30.55; 4.47 0.12  -7.38 -20.89; 8.43 0.34 
PFDA  -3.54 -23.19; 21.15 0.76  -21.73 -35.09; -5.63 0.010  -14.86 -26.33; -1.60 0.029 
18 months            
PFOS  17.55 -0.84; 39.34 0.062  -21.21 -61.54; 61.40 0.51  15.07 -2.49; 35.79 0.096 
PFOA  4.19 -11.76; 23.02 0.63  30.49 -35.31; 163.21 0.46  5.44 -10.28; 23.92 0.52 
PFHxS  7.85 -0.38; 16.76 0.062  -12.42 -55.25; 71.43 0.70  7.54 -0.60; 16.35 0.070 
PFNA  24.43 5.72; 46.45 0.009  -35.28 -64.95; 19.48 0.16  19.18 1.72; 39.62 0.030 
PFDA  25.52 2.00; 54.48 0.032  -22.87 -60.92; 52.24 0.45  20.42 -1.29; 46.90 0.067 
60 months            
PFOS  17.17 -8.66; 50.31 0.21  -16.02 -34.01; 6.87 0.16  -1.34 -17.05; 17.34 0.88 
PFOA  18.31 -10.72; 56.78 0.24  -6.84 -27.26; 19.30 0.57  3.38 -14.16; 24.50 0.73 
PFHxS  4.26 -15.12; 28.08 0.69  4.98 -8.25; 20.13 0.48  4.77 -6.40; 17.26 0.42 
PFNA  -8.85 -23.95; 9.25 0.32  -17.70 -32.30; 0.03 0.050  -13.06 -23.86; -0.72 0.039 
PFDA  -8.99 -23.63; 8.46 0.29  -15.96 -28.91; -0.66 0.042  -12.71 -22.66; -1.48 0.028 
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Table 3. Percentage change in serum-PFAS concentrations per month during exclusive breastfeeding, partial and none. 
   Cohort 5    Cohort 3   Joint  
Exposure nursing change 95% Cl p  change 95% Cl p  change 95% Cl p 
PFOS exclusive 14.76 (13.13, 16.41) <0.001  21.03 (17.02, 25.19) <0.001  15.74 (14.24, 17.26) <0.001 
 mixed   6.32 (5.29, 7.37) <0.001    3.26 (0.32, 6.29)   0.030    5.99 (5.00, 6.98) <0.001 
 none  -0.07 (-0.50, 0.36)   0.75  -0.71 (-1.77, 0.35)   0.19   -0.2 (-0.60, 0.19)   0.31 
PFOA exclusive 16.69 (14.82, 18.60) <0.001  24.05 (19.35, 28.93) <0.001  17.78 (16.05, 19.54) <0.001 
 mixed   7.22 (6.04, 8.41) <0.001    5.08 (1.58, 8.71)   0.004    7.01 (5.88, 8.14) <0.001 
 none   0.8 (0.30, 1.29)   0.002    1.31 (0.04, 2.59)   0.043   0.77 (0.31, 1.23)   0.001 
PFHxS exclusive 23.91 (19.83, 28.12) <0.001   -2.95 (-8.46, 2.88)   0.31  20.56 (16.68, 24.56) <0.001 
 mixed   2.25 (-0.07, 4.61)   0.057  -11.54 (-16.72, -6.04) <0.001    2.1 (-0.19, 4.45)   0.073 
 none -7.91 (-8.83, -6.98) <0.001  -16.82 (-18.70, -14.90) <0.001  -7.48 (-8.38, -6.56) <0.001 
PFNA exclusive 13.77 (12.05, 15.51) <0.001  20.15 (15.82, 24.65) <0.001  14.55 (12.96, 16.16) <0.001 
 mixed   8.55 (7.43, 9.69) <0.001    4.61 (1.37, 7.95)   0.005    8.17 (7.09, 9.25) <0.001 
 none   0.91 (0.45, 1.37) <0.001   -1.29 (-2.44, -0.12)   0.030    0.66 (0.24, 1.09)   0.002 
PFDA exclusive 11.5 (9.83, 13.19) <0.001  14.51 (8.98, 20.32) <0.001  11.45 (9.85, 13.08) <0.001 
 mixed   9.64 (8.51, 10.78) <0.001    5.03 (0.73, 9.51)   0.021    9.49 (8.38, 10.61) <0.001 
 none   4.21 (3.73, 4.69) <0.001    0.29 (-1.24, 1.86)   0.71    4.05 (3.58, 4.51) <0.001 
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Table 4. Effect of doubling in predicted serum concentration of PFOA and PFOA at different ages (in months) with adjustment for  
differences in dependence on breastfeeding in the two cohorts. 
Vaccine /   Cohort 5    Cohort 3     Joint  
Exposure Age change 95% Cl p  change 95% Cl p   change 95% Cl p 
Tetanus              
PFOS   3 -20.03 (-38.88,4.62) 0.10  -24.75 (-53.37,21.42) 0.24   -21.16 (-37.60,-0.38) 0.046 
   6 -13.13 (-30.52,8.62) 0.22  -27.74 (-46.26,-2.86) 0.031   -18.81 (-32.06,-2.99) 0.022 
 12 -6.58 (-22.62,12.78) 0.48  -16.92 (-32.17,1.77) 0.073   -11.50 (-22.91,1.60) 0.083 
PFOA   3 -32.63 (-46.72,-14.82) 0.001  -23.03 (-48.45,14.94) 0.20   -30.35 (-43.20,-14.59) 0.001 
   6 -24.81 (-38.43,-8.19) 0.005  -28.17 (-45.08,-6.07) 0.016   -26.06 (-37.01,-13.20) <0.001 
 12 -16.92 (-30.11,-1.25) 0.035  -17.75 (-32.01,-0.51) 0.044   -17.31 (-27.25,-6.02) 0.004 
Diphtheria              
PFOS   3 -0.90 (-24.02,29.26) 0.95  -54.36 (-73.91,-20.16) 0.006   -15.30 (-33.08,7.21) 0.17 
   6 3.35 (-17.16,28.95) 0.77  -27.40 (-47.47,0.34) 0.052   -7.32 (-22.79,11.25) 0.42 
 12 3.65 (-13.90,24.78) 0.71  -2.70 (-22.31,21.85) 0.81   1.12 (-12.38,16.69) 0.88 
PFOA   3 -12.36 (-30.61,10.69) 0.27  -31.05 (-56.20,8.54) 0.11   -16.87 (-32.35,2.15) 0.079 
   6 -6.42 (-23.28,14.14) 0.51  -16.46 (-37.69,12.02) 0.23   -9.73 (-23.41,6.39) 0.22 
 12 -3.88 (-18.97,14.02) 0.65  2.63 (-16.87,26.69) 0.81   -1.28 (-13.54,12.72) 0.85 
 
